| Source: |
| Type: type of cell death |
| Situation in which a cell actively pursues a course toward death upon receiving certain stimuli. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. |
| 4910- | Sal, | A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent |
| 5123- | Sal, | Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HEK293 |
| 323- | Sal, | AgNPs, | Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Ovarian, | A2780S |
| 1208- | SANG, | Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region |
| - | in-vitro, | OS, | NA |
| 1307- | SANG, | Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway |
| - | in-vitro, | CRC, | HT-29 |
| 5139- | SAS, | Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | U2OS |
| 5041- | SAS, | Cisplatin, | Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism |
| - | in-vitro, | CRC, | NA |
| 1388- | Sco, | Scoulerine promotes cell viability reduction and apoptosis by activating ROS-dependent endoplasmic reticulum stress in colorectal cancer cells |
| - | in-vitro, | CRC, | NA |
| 4483- | Se, | Chit, | Anti-cancer potential of chitosan-starch selenium Nanocomposite: Targeting osteoblastoma and insights of molecular docking |
| - | in-vitro, | OS, | NA |
| 4484- | Se, | Chit, | PEG, | Anti-cancer potential of selenium-chitosan-polyethylene glycol-carvacrol nanocomposites in multiple myeloma U266 cells |
| - | in-vitro, | Melanoma, | U266 |
| 4486- | Se, | Chit, | Selenium-Modified Chitosan Induces HepG2 Cell Apoptosis and Differential Protein Analysis |
| - | in-vitro, | Liver, | HepG2 |
| 4488- | Se, | Chit, | PEG, | Anticancer effect of selenium/chitosan/polyethylene glycol/allyl isothiocyanate nanocomposites against diethylnitrosamine-induced liver cancer in rats |
| - | in-vivo, | Liver, | HepG2 | - | in-vivo, | Nor, | HL7702 |
| 4726- | Se, | Oxy, | Oxygen therapy accelerates apoptosis induced by selenium compounds via regulating Nrf2/MAPK signaling pathway in hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 4714- | Se, | SSE, | SeNPs, | Selenium in cancer management: exploring the therapeutic potential |
| - | Review, | Var, | NA |
| 4734- | SeNPs, | CPT-11, | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
| 4611- | SeNPs, | Rad, | Radioprotective Effect of Selenium Nanoparticles: A Mini Review |
| - | Review, | Var, | NA |
| 4480- | SeNPs, | Chit, | Biogenic synthesized selenium nanoparticles combined chitosan nanoparticles controlled lung cancer growth via ROS generation and mitochondrial damage pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HK-2 |
| 4504- | SeNPs, | Chit, | FA, | doxoR, | pH-responsive selenium nanoparticles stabilized by folate-chitosan delivering doxorubicin for overcoming drug-resistant cancer cells |
| - | in-vitro, | Var, | NA |
| 4501- | SeNPs, | Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | L929 |
| 4469- | SeNPs, | Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential |
| - | Review, | Var, | NA |
| 4471- | SeNPs, | Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis |
| - | in-vitro, | Liver, | HepG2 |
| 4449- | SeNPs, | PEG-nanolized ultrasmall selenium nanoparticles overcome drug resistance in hepatocellular carcinoma HepG2 cells through induction of mitochondria dysfunction |
| - | in-vitro, | Liver, | HepG2 |
| 4451- | SeNPs, | Effects of chitosan-stabilized selenium nanoparticles on cell proliferation, apoptosis and cell cycle pattern in HepG2 cells: comparison with other selenospecies |
| - | in-vitro, | Liver, | HepG2 |
| 4453- | SeNPs, | Selenium Nanoparticles: Green Synthesis and Biomedical Application |
| - | Review, | NA, | NA |
| 3180- | SFN, | Exploring the therapeutic effects of sulforaphane: an in-depth review on endoplasmic reticulum stress modulation across different disease contexts |
| - | Review, | Var, | NA |
| 3181- | SFN, | Effect of sulforaphane on protein expression of Bip/GRP78 and caspase-12 in human hapetocelluar carcinoma HepG-2 cells |
| - | in-vitro, | HCC, | HepG2 |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| 2555- | SFN, | Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis |
| - | Review, | Var, | NA |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 1014- | SFN, | Sulforaphane Modulates Cell Migration and Expression of β-Catenin and Epithelial Mesenchymal Transition Markers in Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1730- | SFN, | Sulforaphane: An emergent anti-cancer stem cell agent |
| - | Review, | Var, | NA |
| 1733- | SFN, | Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal |
| - | in-vitro, | PC, | PanCSC | - | in-vitro, | Nor, | HPNE | - | in-vitro, | Nor, | HNPSC |
| 1735- | SFN, | Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 1723- | SFN, | Sulforaphane as a potential remedy against cancer: Comprehensive mechanistic review |
| - | Review, | Var, | NA |
| 1722- | SFN, | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
| - | Review, | Var, | NA |
| 1498- | SFN, | Prolonged sulforaphane treatment activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in tumorigenic HCT116 colon cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | NCM460 |
| 1459- | SFN, | AF, | Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway |
| - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HepG2 |
| 1471- | SFN, | ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 1467- | SFN, | Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells |
| - | in-vitro, | AML, | U937 |
| 1466- | SFN, | Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway |
| - | vitro+vivo, | Thyroid, | FTC-133 |
| 1465- | SFN, | TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells |
| - | NA, | Bladder, | NA |
| 1464- | SFN, | d,l-Sulforaphane Induces ROS-Dependent Apoptosis in Human Gliomablastoma Cells by Inactivating STAT3 Signaling Pathway |
| - | in-vitro, | GBM, | NA |
| 1463- | SFN, | Sulforaphane induces reactive oxygen species-mediated mitotic arrest and subsequent apoptosis in human bladder cancer 5637 cells |
| - | in-vitro, | Bladder, | 5637 |
| 1461- | SFN, | Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer - contradictory effects and future perspectives |
| - | Review, | BC, | NA |
| 1434- | SFN, | GEM, | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
| - | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
| 1474- | SFN, | Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway |
| - | in-vitro, | Colon, | SW480 |
| 1509- | SFN, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 1497- | SFN, | Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells |
| - | in-vitro, | Nor, | PrEC | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 1480- | SFN, | Sulforaphane Induces Cell Death Through G2/M Phase Arrest and Triggers Apoptosis in HCT 116 Human Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:14 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid